Article
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Blood - 10 Feb 2022
Mill Christopher P, Fiskus Warren, DiNardo Courtney D, Birdwell Christine, Davis John A, Kadia Tapan M, Takahashi Koichi, Short Nicholas, Daver Naval, Ohanian Maro, Borthakur Gautam, Kornblau Steven M, Green Michael R, Qi Yuan, Su Xiaoping, Khoury Joseph D, Bhalla Kapil N
Abstract excerpt
The majority of RUNX1 mutations in acute myeloid leukemia (AML) are missense or deletion-truncation and behave as loss-of-function mutations. Following standard therapy, AML patients expressing mtRUNX1 exhibit inferior clinical outcome than those without mutant RUNX1. Studies presented here demonstrate that as compared with AML cells lacking mtRUNX1, their isogenic counterparts harboring mtRUNX1 display impaired...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.